

ALASKA MEDICAID
Prior Authorization Criteria

**Tezspire™
(tezeplumab-ekko)**

FDA INDICATIONS AND USAGE¹

Tezspire™ is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody (IgG2λ), indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.

APPROVAL CRITERIA^{1,2,3}

1. Patient meets FDA labeling approved age **AND**;
2. Prescribed by or in consultation with a pulmonologist, allergist, or immunologist **AND**;
3. Patient has the diagnosis of severe asthma **AND**;
4. In the preceding year, patient has experienced at least one of the following:
 - a. ≥ 2 exacerbations which required oral or injectable corticosteroid therapy
 - b. ≥ 1 exacerbation resulting in hospitalization **AND**;
6. Must be used as an adjunct therapy to patients receiving both of the following for at least three months:
 - a. a medium to high dose inhaled steroid
 - b. an additional controller medication (e.g. leukotriene modifier, long acting beta agonist, etc..) **AND**;
7. Will not be used for the relief of acute asthma exacerbation or status asthmaticus **AND**;
8. Will not be used concomitantly with any other biologic product for asthma treatment **AND**;

DENIAL CRITERIA¹

1. Failure to meet approval criteria **OR**;
2. Patient is non-adherent to controller medication therapy

CAUTIONS¹

- Tezspire should not be used for treatment of acute asthma symptoms or exacerbations.
- The use of live attenuated vaccines should be avoided in patients receiving Tezspire.
- Do not discontinue systemic or inhaled steroids abruptly on initiation of treatment with Tezspire. Taper gradually, if appropriate.

DURATION OF APPROVAL

- Initial Approval: up to 3 months.
- Reauthorization Approval: up to 12 months.

QUANTITY LIMIT

- Not to exceed 210mg every 28 days.

REFERENCES / FOOTNOTES:

Tezspire™ Criteria
Version: 1
Original: 08/22/2023
Accepted: 09/15/2023
Effective: 11/1/2023

ALASKA MEDICAID
Prior Authorization Criteria

1. Tezspire [prescribing information]. Thousand Oaks, CA; Amgen Inc. and AstraZeneca AB; May 2023
2. Global Initiative for Asthma(GINA). Global strategy for asthma management and prevention (2023 report). Available at <https://ginasthma.org/2023-gina-main-report/>. Accessed 8/21/2023
3. National Asthma Education and Prevention Program: Expert Panel Report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. Available at <https://www.nhlbi.nih.gov/health-topics/guidelines-for-diagnosis-management-of-asthma>. Accessed 07/15/2023.